BR112016016880A2 - Combinação para tratar câncer e seu uso, kit, e composição farmacêutica - Google Patents

Combinação para tratar câncer e seu uso, kit, e composição farmacêutica

Info

Publication number
BR112016016880A2
BR112016016880A2 BR112016016880A BR112016016880A BR112016016880A2 BR 112016016880 A2 BR112016016880 A2 BR 112016016880A2 BR 112016016880 A BR112016016880 A BR 112016016880A BR 112016016880 A BR112016016880 A BR 112016016880A BR 112016016880 A2 BR112016016880 A2 BR 112016016880A2
Authority
BR
Brazil
Prior art keywords
combination
kit
pharmaceutical composition
treat cancer
fluoro
Prior art date
Application number
BR112016016880A
Other languages
English (en)
Inventor
Michael Chan Edward
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112016016880A2 publication Critical patent/BR112016016880A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

COMBINAÇÃO PARA TRATAR CÂNCER E SEU USO, KIT, E COMPOSIÇÃO FARMACÊUTICA. A presente invenção refere-se à preparação de medicamentos para uso no tratamento e métodos de tratamento de câncer do pulmão de células não pequenas em um paciente que compreende: [5-(4-etil-piperazin-1-ilmetil)-piridin-2-il]-[5-fluoro-4-(7-fluoro-3-isopropil-2-metil-3H-benzoimidazol-5-il)-pirimidin-2-il]-amina, ou um sal farmaceuticamente aceitável desta, em combinação, como ainda aqui descrito, com um anticorpo anti-VEGFR2, preferivelmente, ramucirumab.
BR112016016880A 2014-02-26 2015-02-19 Combinação para tratar câncer e seu uso, kit, e composição farmacêutica BR112016016880A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461944811P 2014-02-26 2014-02-26
PCT/US2015/016529 WO2015130540A1 (en) 2014-02-26 2015-02-19 Combination therapy for cancer

Publications (1)

Publication Number Publication Date
BR112016016880A2 true BR112016016880A2 (pt) 2017-10-03

Family

ID=52630493

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016016880A BR112016016880A2 (pt) 2014-02-26 2015-02-19 Combinação para tratar câncer e seu uso, kit, e composição farmacêutica

Country Status (18)

Country Link
US (1) US10238656B2 (pt)
EP (1) EP3110444B1 (pt)
JP (1) JP5948525B1 (pt)
KR (1) KR20160111001A (pt)
CN (1) CN106029097A (pt)
AP (1) AP2016009402A0 (pt)
AU (1) AU2015223359B2 (pt)
BR (1) BR112016016880A2 (pt)
CA (1) CA2936558A1 (pt)
EA (1) EA201691385A1 (pt)
ES (1) ES2659424T3 (pt)
IL (1) IL246761A0 (pt)
MA (1) MA39294B1 (pt)
MX (1) MX2016011045A (pt)
MY (1) MY176219A (pt)
SG (1) SG11201606958YA (pt)
TW (1) TWI558399B (pt)
WO (1) WO2015130540A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201625304A (zh) * 2014-10-24 2016-07-16 美國禮來大藥廠 泌尿上皮癌之療法
CN108883182A (zh) * 2016-04-15 2018-11-23 伊莱利利公司 用于治疗套细胞淋巴瘤的雷莫芦单抗和abemaciclib的组合治疗
EP3502103B1 (en) * 2016-09-09 2022-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor
US20200062836A1 (en) * 2016-11-16 2020-02-27 Eli Lilly And Company THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES
CN112119073A (zh) 2018-04-05 2020-12-22 庄信万丰股份有限公司 阿贝西尼的固态形式、其用途和制备
JP2021517583A (ja) * 2018-04-06 2021-07-26 イーライ リリー アンド カンパニー 小児患者における癌の治療のためのラムシルマブ
WO2020239051A1 (zh) * 2019-05-30 2020-12-03 江苏恒瑞医药股份有限公司 Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途
WO2021030843A1 (en) 2019-08-13 2021-02-18 Johnson Matthey Public Limited Company Solid-state forms of abemaciclib, their use and preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PRODUCING A POLYPEPTIDE
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ATE475431T1 (de) * 2002-03-04 2010-08-15 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6

Also Published As

Publication number Publication date
SG11201606958YA (en) 2016-09-29
TWI558399B (zh) 2016-11-21
AP2016009402A0 (en) 2016-08-31
TW201542209A (zh) 2015-11-16
KR20160111001A (ko) 2016-09-23
MY176219A (en) 2020-07-24
US20170173013A1 (en) 2017-06-22
EP3110444A1 (en) 2017-01-04
ES2659424T3 (es) 2018-03-15
JP2016521262A (ja) 2016-07-21
MA39294A1 (fr) 2018-06-29
AU2015223359A1 (en) 2016-08-11
JP5948525B1 (ja) 2016-07-06
US10238656B2 (en) 2019-03-26
IL246761A0 (en) 2016-08-31
CA2936558A1 (en) 2015-09-03
MX2016011045A (es) 2016-10-28
AU2015223359B2 (en) 2017-06-01
EA201691385A1 (ru) 2016-12-30
WO2015130540A1 (en) 2015-09-03
MA39294B1 (fr) 2018-12-31
CN106029097A (zh) 2016-10-12
EP3110444B1 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
BR112016016880A2 (pt) Combinação para tratar câncer e seu uso, kit, e composição farmacêutica
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
BR112016012410A2 (pt) conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]